Cargando…

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model

Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux(®)) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustafsson, H., Kale, A., Dasu, A., Lund, A., Edqvist, P.-H., Roberg, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691101/
https://www.ncbi.nlm.nih.gov/pubmed/28756482
http://dx.doi.org/10.1007/s12013-017-0814-5
_version_ 1783279727818047488
author Gustafsson, H.
Kale, A.
Dasu, A.
Lund, A.
Edqvist, P.-H.
Roberg, K.
author_facet Gustafsson, H.
Kale, A.
Dasu, A.
Lund, A.
Edqvist, P.-H.
Roberg, K.
author_sort Gustafsson, H.
collection PubMed
description Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux(®)) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on female BALB/c (nu/nu) nude mice. Mice with xenografts were given three injections of intraperitoneal cetuximab or phosphate-buffered saline, and the tumour volume was recorded continuously. After treatment the tumour partial oxygen pressure was measured by LiPc electron paramagnetic resonance oximetry and the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Ki-67, MCT1, MCT4, GLUT1, CAIX and HIF-1α were investigated by immunohistochemistry. In xenografts from both cell lines (UT-SCC-2 and UT-SCC-14) cetuximab had effect on the tumour volume but the effect was more pronounced on UT-SCC-14 xenografts. A higher tumour oxygenation was measured in cetuximab-treated tumours from both cell lines compared to untreated controls. Immunocytochemical staining after cetuximab treatment shows a significantly decreased expression of EGFR, pEGFR, Ki67, CAIX and nuclear HIF-1α in UT-SCC-14 tumours compared to untreated controls. MCT1 and GLUT1 were significantly decreased in tumours from both cell lines but more pronounced in UT-SCC-14 tumours. Taken together, our results show that cetuximab treatment decreases the tumour growth and increases the tumour partial oxygen pressure of HNSCC xenografts. Furthermore we found a potential connection between the partial oxygen pressure of the tumours and the expression of proteins involved in tumour growth, metabolism and hypoxia.
format Online
Article
Text
id pubmed-5691101
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-56911012017-11-30 EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model Gustafsson, H. Kale, A. Dasu, A. Lund, A. Edqvist, P.-H. Roberg, K. Cell Biochem Biophys Original Paper Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux(®)) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on female BALB/c (nu/nu) nude mice. Mice with xenografts were given three injections of intraperitoneal cetuximab or phosphate-buffered saline, and the tumour volume was recorded continuously. After treatment the tumour partial oxygen pressure was measured by LiPc electron paramagnetic resonance oximetry and the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Ki-67, MCT1, MCT4, GLUT1, CAIX and HIF-1α were investigated by immunohistochemistry. In xenografts from both cell lines (UT-SCC-2 and UT-SCC-14) cetuximab had effect on the tumour volume but the effect was more pronounced on UT-SCC-14 xenografts. A higher tumour oxygenation was measured in cetuximab-treated tumours from both cell lines compared to untreated controls. Immunocytochemical staining after cetuximab treatment shows a significantly decreased expression of EGFR, pEGFR, Ki67, CAIX and nuclear HIF-1α in UT-SCC-14 tumours compared to untreated controls. MCT1 and GLUT1 were significantly decreased in tumours from both cell lines but more pronounced in UT-SCC-14 tumours. Taken together, our results show that cetuximab treatment decreases the tumour growth and increases the tumour partial oxygen pressure of HNSCC xenografts. Furthermore we found a potential connection between the partial oxygen pressure of the tumours and the expression of proteins involved in tumour growth, metabolism and hypoxia. Springer US 2017-07-29 2017 /pmc/articles/PMC5691101/ /pubmed/28756482 http://dx.doi.org/10.1007/s12013-017-0814-5 Text en © The Author(s) 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Gustafsson, H.
Kale, A.
Dasu, A.
Lund, A.
Edqvist, P.-H.
Roberg, K.
EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title_full EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title_fullStr EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title_full_unstemmed EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title_short EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
title_sort epr oximetry of cetuximab-treated head-and-neck tumours in a mouse model
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691101/
https://www.ncbi.nlm.nih.gov/pubmed/28756482
http://dx.doi.org/10.1007/s12013-017-0814-5
work_keys_str_mv AT gustafssonh eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel
AT kalea eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel
AT dasua eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel
AT lunda eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel
AT edqvistph eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel
AT robergk eproximetryofcetuximabtreatedheadandnecktumoursinamousemodel